Coya Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Coya Therapeutics, Inc. (COYA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 4.72 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- Coya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 4.68M shares, a 20.78% increase year-over-year.
- Coya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 3.88M shares, a 2.74% decline year-over-year.
- Coya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 3.98M shares, a 24.95% increase year-over-year.
- Coya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 3.19M shares, a 80.73% increase year-over-year.
- Coya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 3.79M shares, a 24.61% increase from fiscal 2024.
- Coya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 3.04M shares, a 16.05% decline from fiscal 2023.
- Coya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 3.63M shares, a 21.58% decline from fiscal 2022.
- Coya Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 4.62M shares, a 162.06% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.72M shares 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 4.68M shares 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 3.79M shares 10-K · filed 2026-03-16 | |||
| 2025-09-30 | 3.84M shares 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 3.78M shares 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | 3.88M shares 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | 3.04M shares 10-K · filed 2026-03-16 | |||
| 2024-09-30 | 4.52M shares 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | 4.49M shares 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 3.98M shares 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | 3.63M shares 10-K · filed 2025-03-18 | |||
| 2023-09-30 | 3.41M shares 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 3.30M shares 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | 3.19M shares 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 4.62M shares 10-K · filed 2024-03-19 | |||
| 2022-09-30 | 2.93M shares 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | 2.96M shares 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 1.76M shares 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | 1.76M shares 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |